In a double blind placebo-controlled cross-over study the effect of cilostazol on aura induction and endothelial response is tested in patient with migraine with aura.
Migraine with aura is associated to an increased risk of stroke. The mechanism behind such increased risk is not fully understood. Cilostazol induce headache and migraine in migraine patients and is used as secondary prevention of stroke. The effect on aura induction is not known. We investigate the aura inducing potential of cilostazol and associated changes in endothelial function.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
16
Single oral administration of active or placebo one week apart
Herlev Hospital, Dept Neurology
Herlev, Denmark
Aura
Induction of aura reported by an aura diary for 24 hours post medication
Time frame: 24 hours
Migraine
Induction of headache resembling usual migraine attacks
Time frame: 24 hours
Endothelial response
Measurement of endothelial response by Endopat2000 before and after administration of placebo and cilostazol
Time frame: 3 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.